Giardini Alessandro, Donti Andrea, Formigari Roberto, Salomone Luisa, Palareti Gualtiero, Guidetti Donata, Picchio Fernando Maria
Pediatric Cardiology and Adult Congenital Unit, University of Bologna, Bologna, Italy.
Catheter Cardiovasc Interv. 2006 Apr;67(4):625-9. doi: 10.1002/ccd.20699.
To assess the long-term results of transcatheter patent foramen ovale (PFO) closure on migraine headache with aura (MHA) and on the risk of recurrent stroke.
Transcatheter PFO closure is associated with an early improvement of MHA, and a reduction or the risk of recurrent cerebral ischemia, but the long-term outcome after the procedure is unknown.
We analyzed follow-up data of 38 consecutive patients who had undergone transcatheter PFO closure at our institution because of cryptogenic stroke and had been followed-up for at least 3 years after the procedure. Mean age at closure was 43 +/- 13 years. Thirteen patients (34%) had a diagnosis of MHA made by the primary care physician or the referring neurologist. Migraine disability assessment questionnaire (MIDAS) was used to assess MHA incidence and severity.
After a mean follow-up of 4.8 +/- 1.4 years, two patients had a recurrent stroke (13 and 15 months after the procedure, respectively). Recurrence rate 5 years after the procedure was 5.3%. After 4.9 +/- 1.4 years from the intervention, 12/13 patients (92%, 95% CI 65-99%) had complete resolution in their MHA. Overall, MIDAS score decreased significantly (38.6 +/- 26.3 vs. 4.4 +/- 5.1, P < 0.0001) after the procedure. One patient did not report any improvement of MHA after transcatheter PFO closure, whereas one patient reported a severe relapse of MHA about 1 year after PFO closure. Freedom from recurrent MHA 5 years after the procedure was 85% (95% CI 57-97%).
The rate of recurrent cerebral ischemia and recurrent MHA seems to be low at long-term follow-up after transcatheter PFO closure. Recurrent cerebral ischemia and relapse of MHA seem to be confined to the first 15 months after the procedure.
评估经导管封堵卵圆孔未闭(PFO)治疗伴先兆偏头痛(MHA)的长期疗效以及复发性卒中风险。
经导管封堵PFO与MHA的早期改善以及复发性脑缺血风险的降低相关,但该手术后的长期结果尚不清楚。
我们分析了38例因隐源性卒中在我院接受经导管PFO封堵术且术后至少随访3年的连续患者的随访数据。封堵时的平均年龄为43±13岁。13例患者(34%)由初级保健医生或转诊的神经科医生诊断为MHA。采用偏头痛残疾评估问卷(MIDAS)评估MHA的发生率和严重程度。
平均随访4.8±1.4年后,2例患者发生复发性卒中(分别在术后13个月和15个月)。术后5年的复发率为5.3%。干预后4.9±1.4年,13例患者中有12例(92%,95%CI 65-99%)的MHA完全缓解。总体而言,术后MIDAS评分显著降低(38.6±26.3对4.4±5.1,P<0.0001)。1例患者经导管封堵PFO后MHA无改善,而1例患者在PFO封堵术后约1年报告MHA严重复发。术后5年无复发性MHA的比例为85%(95%CI 57-97%)。
经导管封堵PFO术后长期随访时,复发性脑缺血和复发性MHA的发生率似乎较低。复发性脑缺血和MHA复发似乎局限于术后的前15个月。